🇺🇸

US SEC Filing Intelligence

· daily

Mega Contracts Monitor ($100M+) — August 29, 2026

Across seven mega-contracts worth $2.17 billion, the vast majority are civilian agency awards (6 of 7), led by a dominant $892.8 million Department of Education debt management contract to MAXIMUS INC. Defense-related awards are notably absent—only one contract touches defense-adjacent (NOAA aircraft for General Dynamics). The highest-conviction signal is MAXIMUS's decade-plus, fixed-price win, though its performance risk is material. A key risk is near-term lumpy revenue concentration at UnitedHealth Group (OptumRx), which secured $212.6 million in two three-month VA PBM delivery orders with no outlays yet. Overall, the digest points to steady civilian demand for operational services and specialized aviation, but with limited defense exposure and execution risk on fixed-price structures.

7 total filings
· daily

High-Value Federal Grants ($5M+) — August 29, 2026

This digest covers $2.17 billion in high-value federal obligations from a single day (August 29, 2026), with only 1 of 7 contracts defense-related, underscoring a civilian-heavy procurement stream. The dominant theme is large, long-duration service contracts at civilian agencies, led by a $892.8 million MAXIMUS FEDERAL SERVICES contract with the Department of Education for debt management, and a $427.6 million Navarro Research award from the Department of Energy for environmental remediation. The highest-conviction signal is the MAXIMUS win, which represents a decade-plus revenue stream with $544 million already outlaid, though its fixed-price structure introduces performance risk. A key risk is the $106.3 million OptumRx VA contract with zero outlays and a short three-month performance window, creating lumpy revenue and execution uncertainty for UnitedHealth Group. Overall, the digest signals stable civilian agency spending on operational services, but with limited defense exposure and notable concentration risk in two OptumRx awards to the same parent company.

7 total filings
· daily

DOE Energy Grants — August 29, 2026

This digest covers a single, large civilian Department of Energy (DOE) contract worth $427.6 million awarded to Navarro Research and Engineering, Inc. The contract is entirely non-defense, reflecting sustained federal commitment to environmental remediation and long-term stewardship of legacy nuclear sites. While the contract provides a substantial, low-risk revenue baseline for the small business (an estimated $63.8 million/year), the cost-plus-award-fee structure limits upside margin volatility. The highest-conviction signal is the low outlay rate (~23%), suggesting ~$330.5 million in future revenue remains unrealized. A key risk is that the contract's reported performance period ended in August 2021, meaning the current status and any extensions are unresolved and require monitoring for continuation or re-compete.

1 total filings
· daily

General Federal Contracts — August 29, 2026

These 7 contracts, totaling $2.17 billion across a single day in August 2026, are overwhelmingly civilian in nature (1 defense-related, but defense-related contract at just $251 million from NOAA/Gulfstream). The dominant theme is steady-state civilian agency spending, led by a massive $892.8 million Department of Education debt management win for MAXIMUS and two separate $106 million short-term VA pharmacy benefit management awards to UnitedHealth Group’s OptumRx. The highest-conviction bullish signal is MAXIMUS’s decade-long, fixed-price contract with strong past performance ($544M outlayed), though the firm-fixed-price structure carries medium execution risk. A key risk is the short three-month performance periods for OptumRx awards, creating lumpy revenue recognition and margin compression risk for UnitedHealth Group. Aggregate signal strength averages 6.3/10, indicating moderate conviction across the set.

7 total filings
· daily

Big Pharma Approvals — August 28, 2026

During the one-day period of August 28, 2026, two label expansion approvals were granted, with no NMEs, biosimilars, or new label expansions in the traditional sense, categorized as 'Other' due to the FALLBACK designation. The approvals span metabolic (tirzepatide) and immunology/oncology (nipocalimab) therapeutic areas, indicating continued expansion of established blockbuster franchises rather than new molecular entity innovation. The highest-conviction signal is Eli Lilly's label expansion for tirzepatide (ZEPBOUND), reinforcing its dominance in the GLP-1/GIP metabolic space, with a moderate bullish signal (5/10 strength). Key risks include potential IRA negotiation for small molecules (tirzepatide) and competitive pressure in the anti-FcRn space for nipocalimab. Overall, the period reflects incremental label expansions with moderate commercial impact, and investors should monitor payer coverage and competitive dynamics.

2 total filings
· daily

Orphan Drug Approvals — August 28, 2026

This digest covers three same-day label expansion approvals (August 24–25, 2026) under the Orphan Drug stream, with zero NMEs or biosimilars. The approvals are for ZANIDATAMAB-HRII (ZIIHERA) by JAZZ PHARMS, TISLELIZUMAB-JSGR (TEVIMBRA) by BEIGENE, and NIPOCALIMAB-AAHU (IMAAVY) by JANSSEN BIOTECH. All three are designated as 'FALLBACK' approvals and rated bullish (5/10 strength, 5/10 materiality), but the total lack of commercial detail (peak sales, exclusivity, pricing power) renders their immediate investment signal weak. The highest-conviction signal is BEIGENE’s TEVIMBRA label expansion, as it extends the anti-PD-1’s reach into potentially larger oncology indications, reinforcing BEIGENE’s commercial execution in global immuno-oncology. However, the absence of specific indication data, exclusivity periods, or competitor responses limits actionable conclusions.

3 total filings
· daily

Federal Construction & Infrastructure Contracts — August 28, 2026

This digest covers a single, high-value civilian infrastructure contract totaling $374.9 million awarded to Hensel Phelps Construction Co. by the General Services Administration for the design and construction of the Raul Hector Castro Land Port of Entry in Arizona. The contract is entirely civilian (0% defense-related) and reflects steady federal investment in border infrastructure under full and open competition. The highest-conviction signal is neutral, given the firm-fixed-price structure over a nearly six-year performance period, which introduces material execution and margin risk. Key watch items include construction material cost trends in the Arizona border region and GSA outlay data to gauge revenue recognition pace.

1 total filings
· daily

Defense Manufacturing Contracts — August 28, 2026

A single $99.8M cost-plus-fixed-fee contract from NASA to Lockheed Martin Corp for Mars Ascent Vehicle R&D services dominates this digest, representing 100% of the total obligation and a 0/1 defense-to-civilian split. The contract, awarded under full and open competition, underscores Lockheed's entrenched competitive moat in deep space exploration hardware, with $96.4M already outlayed signaling strong execution progress. The highest-conviction signal is the low-risk cost-plus pricing structure, which ensures stable margins and predictable revenue of ~$36.6M annually through September 2025. Key risks include potential budget cuts to NASA's Mars Sample Return mission and the exercise of $274.4M in options, which would materially increase Lockheed's exposure to this program.

1 total filings
· daily

DHS Homeland Security Contracts — August 28, 2026

This digest covers two Department of Homeland Security contracts totaling $782.1 million, both civilian (non-defense) awards, with an average signal strength of 5.5/10. The dominant theme is DHS investment in IT services and aviation support, led by a $580.4 million IBM delivery order for FEMA's EADIS software development, though its negative outlay raises revenue realization concerns. The highest-conviction signal is a $201.7 million sole-source award to PAE Aviation (Amentum) for CBP aviation maintenance, indicating a strong incumbent position in border security logistics. A key risk is the IBM contract's negative outlay, suggesting potential inactivity or termination, which could mislead top-line revenue expectations for investors.

2 total filings
· daily

VA Healthcare & Services Contracts — August 28, 2026

This digest covers a single, large civilian contract from the Department of Veterans Affairs (VA) totaling $159.2 million, with no defense-related exposure. The award to OptumRx Administrative Services, LLC, a subsidiary of UnitedHealth Group, is for a four-month pharmacy benefit management (PBM) delivery order under a firm-fixed-price structure, providing high revenue visibility and low execution risk for the period. The highest-conviction signal is the bullish near-term cash flow for UnitedHealth Group, though the short performance window and lack of follow-on orders create a concentration risk. Key watch items include the potential for additional task orders under the same vehicle and the upcoming re-compete for VA PBM services.

1 total filings
· daily

New Federal Contractors — August 28, 2026

In the period of August 28, 2026, six new federal contracts totaling $1.496 billion were awarded, all from civilian agencies with zero defense-related awards. The dominant theme is civilian infrastructure and services, led by IBM's $580.4 million FEMA IT delivery order (though with negative outlays), Hensel Phelps' $374.9 million GSA border port construction, and PAE Aviation's $201.7 million DHS aviation maintenance contract. The highest-conviction signal is OptumRx's $159.2 million VA pharmacy benefit management order, which is a competitive win with strong revenue visibility. Key risks include IBM's contract showing no actual spending, potential execution risk on Hensel Phelps' fixed-price construction, and the short performance periods of several awards.

6 total filings
· daily

Significant Contract Modifications ($10M+) — August 28, 2026

This digest covers six significant contract modifications totaling $1.50 billion, all awarded by civilian agencies with zero defense-related obligations. The dominant theme is federal investment in border security and healthcare IT, with the Department of Homeland Security (DHS) accounting for $782.1 million (52% of total) across three awards. The highest-conviction signal is OptumRx's $159.2 million VA pharmacy benefit management delivery order, which annualizes to ~$477.6 million and reinforces UnitedHealth Group's competitive position in federal healthcare. A key risk is the $580.4 million IBM-FEMA contract showing negative outlays ($-23,548), suggesting the award may be inactive or terminated, raising questions about revenue recognition for a contract that appears to be a legacy award from 2008.

6 total filings
· daily

Contract Deobligations Alert — August 28, 2026

This digest covers $1.5 billion in total obligations across six civilian-agency contracts, with zero defense-related awards. The dominant theme is federal infrastructure and IT services, led by a $580.4 million IBM-FEMA delivery order (though with negative outlays signaling potential dormancy), a $374.9 million Hensel Phelps GSA border port construction contract, and a $201.7 million sole-source PAE/Amentum aviation maintenance award from DHS. The highest-conviction signal is the $159.2 million OptumRx VA pharmacy benefit management order, which provides predictable near-term revenue for UnitedHealth Group. Key risks include the IBM contract’s negligible cash flow and the fixed-price risk on Hensel Phelps’ long-duration border project.

6 total filings
· daily

Contract Option Exercises — August 28, 2026

Over a single-day period (August 28, 2026), six contract option exercises totaling $1.497 billion were obligated, with zero defense-related awards—a stark civilian and space-sector tilt. The dominant payer was the Department of Homeland Security (FEMA and CBP), contributing $782 million, or 52% of the aggregate. The highest-conviction signals are bullish for Lockheed Martin on its $99.8 million Mars Ascent Vehicle R&D award (high outlay progress) and OptumRx’s $159 million short-duration PBM win at the VA. However, the largest obligation—IBM’s $580 million FEMA software contract from 2008—shows negative outlays ($-23,548), raising serious questions about revenue recognition or contract viability. Key risk: the IBM contract’s dormant status could signal execution problems or funding disputes, while concentration in DHS procurement exposes investors to border-security budget continuity post-CR.

6 total filings
· daily

S&P 500 Technology Sector SEC Filings — August 28, 2026

The 8 filings from the S&P 500 Technology sector reveal a bifurcated landscape: strong revenue growth driven by data center and cloud demand (Marvell +36.5% YoY, Autodesk +16.1% YoY) is offset by rising R&D costs and insider selling. Marvell's Q2 FY26 results show robust top-line growth and margin expansion (+270 bps gross margin), but a six-month net income decline of 8.1% due to non-operating charges signals underlying volatility. Autodesk's Q2 FY27 beat is a standout, with net income surging 57.2% YoY and cash flow from operations up 43.4%, though increased debt warrants monitoring. Insider activity is notably bearish: IBM's CEO acquired $2M in phantom stock (bullish), but two other IBM insiders and directors at Intuit, Analog Devices, and Micron sold shares, totaling over $6.4M in disposals. Capital allocation trends are mixed, with Marvell issuing $2B in convertible preferred stock for M&A, while Autodesk's cash position doubled to $4.1B, suggesting potential for increased shareholder returns. The sector theme is 'growth at a cost,' as companies invest heavily in AI infrastructure, compressing near-term margins but positioning for long-term gains. Key catalysts include Marvell's data center momentum and Autodesk's subscription revenue growth, while risks center on insider selling and rising debt levels.

8 high priority 8 total filings
· daily

Nasdaq 100 Stocks SEC Filings — August 28, 2026

The four filings from NASDAQ-100 constituents today are dominated by insider selling activity, with all four companies reporting open-market sales by directors or officers. While the individual transaction sizes are modest (ranging from ~$21K to ~$375K), the pattern of simultaneous selling across Analog Devices, Intuit, Micron Technology, and CoreWeave warrants attention. Notably, two of the four sales (ADI and CoreWeave) were executed under Rule 10b5-1 plans, suggesting pre-planned diversification rather than reactive bearishness. No period-over-period comparisons, forward-looking guidance, capital allocation changes, or M&A activity were disclosed in these filings. The lack of bullish signals or positive catalysts in any filing creates a cautious near-term tone for these holdings. The most material insider sale was Analog Devices' director selling $375K, while Micron's director sale of $28K is negligible. Overall, the digest signals a defensive posture among insiders in the tech sector, though the small scale and pre-planned nature of most trades mitigate alarm.

4 high priority 4 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — August 28, 2026

This intelligence brief covers 39 pre-analyzed SEC filings (SC 13D/G) with enriched data, focused on activist and institutional activity in US equities. The most prominent theme is a surge of passive institutional positions, with entities like Orca Capital AG filing five separate 13Gs across disparate micro-cap companies (Jupiter Neurosciences, NFT Ltd, Elong Power), and WhiteRock Wealth Design filing 13Gs in two small regional banks (Security Midwest, PFS Bancorp). Activist signals are concentrated: a clear activist campaign is escalating at **Evogene Ltd.** (19.35% holder publicly opposing board nominees), while B. Riley’s **Biomerica** stake (10.03%) includes a board appointment right. Notable insider selling overhangs were identified at **Quantum-Si Inc.** (a 10b5-1 plan to sell up to 8.9M shares) and **CBL & Associates** (291K shares sold by top holder). A significant related-party stake was built in **Expion360** (now Expion Energy) via a $4.5M convertible note for oil & gas acquisitions, and CATL (a $100B+ battery giant) indirectly acquired 11.4% of **VNET Group**. No pervasive period-over-period revenue or margin trends were available as these are ownership filings, not financial statements.

21 high priority 18 medium 39 total filings
· daily

Federal IT & Cybersecurity Contracts — August 28, 2026

This digest covers two civilian federal IT contracts totaling $661.3 million, with zero defense-related awards, signaling continued but measured investment in legacy IT infrastructure by agencies like DHS/FEMA and HHS/CMS. The dominant theme is custom computer programming services for critical government functions, with IBM's $580.4 million FEMA delivery order being the largest but showing a negative outlay of -$23,548, raising concerns about revenue realization. Peraton's $80.9 million CMS contract for Medicare Part B claims processing indicates stable near-term funding but faces long-term modernization risk. The highest-conviction signal is the neutral outlook on both contracts due to execution risks and uncertain revenue streams, with a key watch item being whether IBM's contract is active or terminated.

2 total filings
· daily

NASA & Space Contracts Intelligence — August 28, 2026

The digest covers a single NASA contract valued at $99.8 million to Lockheed Martin for Mars Ascent Vehicle R&D, with a total potential value of $274.4 million including options. This is a civilian space contract (0 defense-related) with an average signal strength of 7/10, reflecting Lockheed's strong competitive position in deep space exploration. The cost-plus-fixed-fee structure minimizes profit risk for Lockheed, making this a stable revenue stream, but the contract's materiality is moderate given it represents a small fraction of Lockheed's overall revenue. Key risks include NASA's Mars Sample Return budget uncertainties and potential delays in option exercises.

1 total filings
· daily

All HHS Contracts — August 28, 2026

This digest covers a single $80.86 million HHS contract awarded to Peraton Inc. for Medicare Part B claims processing support, representing 100% civilian exposure with no defense-related awards. The contract is a time-and-materials delivery order for a critical legacy IT function, signaling stable near-term revenue for Peraton but limited public equity impact given its private equity ownership. The highest-conviction signal is neutral, reflecting the balance of sustained funding for a core Medicare system against long-term modernization risks. Key watch items include option exercise over the next four years and potential CMS modernization initiatives that could disrupt contract longevity.

1 total filings